Dana Cernea

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

Olivier Chinot, Wolfgang Wick, Warren Mason et al. · New England Journal of Medicine · 2014 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jérôme Fayette, Lori J. Wirth, Cristina Oprean et al. · Frontiers in Oncology · 2016 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Alba A. Brandes, Miguel Gil‐Gil, Frank Saran et al. · The Oncologist · 2018 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

Roger Henriksson, Andrew Bottomley, Warren Mason et al. · Journal of Clinical Oncology · 2013 · 36 citations

Medicine, Oncology, Pharmacotherapy +17

Functional and molecular characterization of glioblastoma multiforme-derived cancer stem cells.

Ciprian Tomuleasa, Dan Rus-Ciucă, H Ioani et al. · PubMed · 2010 · 21 citations

Medicine, Cancer Biology, Cell Biology +17